Brian J. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brian J. Thomas has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Donald H. Burke
Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri
17 shared publications - Benjamin J. Cryer
Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO 65212, USA
14 shared publications - Lee-Ann H. Allen
Affiliations Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, Missouri, United States of America, Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America
14 shared publications - Margaret J. Lange
Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO 65212, USA
14 shared publications - Mark A. Daniels
Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri
14 shared publications - Sydney M. Escobar
Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri
14 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Media from DUSP11 siRNA treated cells induces ISG expression in HEK293FT
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Media from DUSP11 siRNA treated cells induces ISG expression in HEK293FT
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Individual tumor trajectories and endpoint tumor evaluation
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Individual tumor trajectories and endpoint tumor evaluation
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
DUSP11 knockdown decreases cell viability of breast and skin but not lymphoma, leukemia, or liver cancer cell lines
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
DUSP11 knockdown decreases cell viability of breast and skin but not lymphoma, leukemia, or liver cancer cell lines
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
DUSP11 expression is correlated with patient survival for multiple cancer types and subtypes
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
DUSP11 expression is correlated with patient survival for multiple cancer types and subtypes
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
MHC class II expression on peripheral NK cells is increased in mice implanted with D1 siRNA treated cells
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
MHC class II expression on peripheral NK cells is increased in mice implanted with D1 siRNA treated cells
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
RIG-I, but not other pattern recognition receptors, is required for the innate immune response and cell viability phenotype in lung adenocarcinoma
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
RIG-I, but not other pattern recognition receptors, is required for the innate immune response and cell viability phenotype in lung adenocarcinoma
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
The discovery of immune checkpoints and the rapid growth of immuno-oncology have sparked efforts to utilize the immune system to treat a wide range of cancer types/subtypes. Although the major focus of immuno-oncology over the past decades has been to manipulate the adaptive immune system, recent attention has been given to manipulating the innate immune system to treat cancer and/or to enhance adaptive responses. In this study, we detailed the intracellular protein dual specificity phosphatase 11 (DUSP11) as an innate immune checkpoint in non–small cell lung cancer adenocarcinoma (LUAD). The expression of this atypical phosphatase was correlated with patient survival for multiple cancer types, and we reported here that its activity was important for the viability of lung cancer cells in vitro. Specifically, we demonstrated that DUSP11 knockdown in LUAD cells induces apoptosis and an innate immune response capable of activating other cells in vitro, and we provided evidence that these phenotypes are primarily mediated by the pattern recognition receptor, retinoic acid–inducible gene I. Finally, we showed that the expression of DUSP11 was important for tumor engraftment and growth of human LUAD in mice. Overall, these data are the first to establish DUSP11 as an immunosuppressive, pro-neoplastic, and potentially targetable protein in LUAD. In addition, our data suggest that the anticancer mechanisms induced by diminishing the activity of DUSP11 are likely to be generalizable to other cancer types such as breast and skin cancers, warranting future investigation and highlighting therapeutic potential.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
The discovery of immune checkpoints and the rapid growth of immuno-oncology have sparked efforts to utilize the immune system to treat a wide range of cancer types/subtypes. Although the major focus of immuno-oncology over the past decades has been to manipulate the adaptive immune system, recent attention has been given to manipulating the innate immune system to treat cancer and/or to enhance adaptive responses. In this study, we detailed the intracellular protein dual specificity phosphatase 11 (DUSP11) as an innate immune checkpoint in non–small cell lung cancer adenocarcinoma (LUAD). The expression of this atypical phosphatase was correlated with patient survival for multiple cancer types, and we reported here that its activity was important for the viability of lung cancer cells in vitro. Specifically, we demonstrated that DUSP11 knockdown in LUAD cells induces apoptosis and an innate immune response capable of activating other cells in vitro, and we provided evidence that these phenotypes are primarily mediated by the pattern recognition receptor, retinoic acid–inducible gene I. Finally, we showed that the expression of DUSP11 was important for tumor engraftment and growth of human LUAD in mice. Overall, these data are the first to establish DUSP11 as an immunosuppressive, pro-neoplastic, and potentially targetable protein in LUAD. In addition, our data suggest that the anticancer mechanisms induced by diminishing the activity of DUSP11 are likely to be generalizable to other cancer types such as breast and skin cancers, warranting future investigation and highlighting therapeutic potential.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Cell type/lineage differentiation and activation status of hPBMCs from individual donors
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Cell type/lineage differentiation and activation status of hPBMCs from individual donors
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Flow cytometry gating strategies of mouse and human peripheral blood mononuclear cells
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma
Flow cytometry gating strategies of mouse and human peripheral blood mononuclear cells